KemPharm focuses on the discovery and development of new chemical entities to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) prodrug approach. KemPharm's most advanced prodrug candidate KP201 (NDA Q2 2014) has the potential to reduce abuse and opioid-induced constipation. KP201's rapid development timeline may allow for a substantial near-term share of the large opioid pain market.